Skip to main content
. 2021 Jun 17;11(7):2033–2040. doi: 10.1002/2211-5463.13212

Fig. 2.

Fig. 2

C188‐9 treatment prevents ISO‐induced left ventricular dilatation and dysfunction in mice. C57BL/6 mice aged 10 weeks were administered ISO perfusion with or without C188‐9 treatment. (A) Scheme of C188‐9 treatment in the ISO‐induced mouse model. Mice received ISO perfusion, echocardiography was performed, and heart tissues were collected on day 21. (B) Representative M‐mode echocardiography of the left ventricular chamber. (C, D) Statistical analysis of ejection fraction (EF) (C) and fractional shortening (FS) (D). Saline group, n = 5; ISO group, n = 7; *P < 0.05, ISO‐vehicle vs. saline‐vehicle. # P < 0.05, ISO‐C188‐9 vs. ISO‐vehicle. Two‐way ANOVA, followed by Tukey's post hoc test. (E, F) Heart weight‐to‐body weight ratio (HW/BW) (E) and heart weight‐to‐tibia length ratio (HW/TL) (F) were assessed. Saline group, n = 5; ISO group, n = 7; *P < 0.05, ISO‐vehicle vs. saline‐vehicle. # P < 0.05, ISO‐C188‐9 vs ISO‐vehicle. Two‐way ANOVA, followed by Tukey's post hoc test. (G, H) qRT‐PCR of ANF (G) and BNP (H) mRNA levels in ISO or/and C188‐9‐treated mouse heart tissues. n = 6. *P < 0.05, ISO‐vehicle vs. saline‐vehicle. # P < 0.05, ISO‐C188‐9 vs. ISO‐vehicle. Two‐way ANOVA, followed by Tukey's post hoc test. Data are presented as mean ± SEM.